Harmony Biosciences Files 8-K on Financials

Ticker: HRMY · Form: 8-K · Filed: 2025-10-23T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, results-of-operations, filing

TL;DR

Harmony Biosciences dropped an 8-K on Oct 23rd detailing their financial condition. Check it out.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on October 23, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.

Why It Matters

This 8-K filing provides crucial updates on Harmony Biosciences' financial performance and condition, which is essential for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any significant new risks or negative developments.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Harmony Biosciences Holdings, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.

When was this 8-K report filed?

This 8-K report was filed on October 23, 2025.

Where are Harmony Biosciences Holdings, Inc.'s principal executive offices located?

Harmony Biosciences Holdings, Inc.'s principal executive offices are located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462.

In which state was Harmony Biosciences Holdings, Inc. incorporated?

Harmony Biosciences Holdings, Inc. was incorporated in Delaware.

What is the Standard Industrial Classification (SIC) code for Harmony Biosciences Holdings, Inc.?

The Standard Industrial Classification (SIC) code for Harmony Biosciences Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001104659-25-101688.txt : 20251023 0001104659-25-101688.hdr.sgml : 20251023 20251023081512 ACCESSION NUMBER: 0001104659-25-101688 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20251023 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251023 DATE AS OF CHANGE: 20251023 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 251411463 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20251023x8k.htm 8-K HARMONY BIOSCIENCES HOLDINGS, INC._October 23, 2025 0001802665 false 0001802665 2025-10-23 2025-10-23 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of report (Date of earliest event reported): October 23, 2025 ​ HARMONY BIOSCIENCES HOLDINGS, INC . (Exact name of registrant as specified in its charter) ​ ​ ​ ​ Delaware 001-39450 82-2279923 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) ​ 630 W. Germantown Pike , Suite 215 Plymouth Meeting , PA 19462 (Address of principal executive offices) (Zip Code) ( 484 ) 539-9800 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​      Trading      Name of each exchange Title of each class ​ Symbol(s) ​ on which registered Common Stock, $0.00001 par value per share ​ HRMY ​ The Nasdaq Global Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 2.02.     Results of Operations and Financial Condition.       On October 23, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary net product revenue for the third quarter of 2025. In addition, the Company provided updated guidance related to 2025 net product revenue. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorpora

View on Read The Filing